Malic Acid

Malic Acid

SCHEMBL121545

O=C(O)CC(O)C(=O)O.[Zn]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F

The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.94
SLC22A6 Q4U2R8 1/20 0.53
TET2 Q6N021 6/20 0.52
TET3 O43151 2/20 0.52
TET1 Q8NFU7 1/20 0.52
KDM4A O75164 2/20 0.50
KDM4C Q9H3R0 2/20 0.50
KDM2A Q9Y2K7 2/20 0.50
OR51E2 Q9H255 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
GABRR1 P24046 2/20 0.43
LMNA P02545 1/20 0.43
KMO O15229 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Malic Acid SCHEMBL20560637 0.97 SMN1; SMN2 (0.88) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL27558806 0.97 SMN1; SMN2 (0.88) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL714313 0.97 SMN1; SMN2 (0.88) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL20366115 0.97 SMN1; SMN2 (0.88) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL31673494 0.97
Malic Acid SCHEMBL98496 0.97
Malic Acid SCHEMBL31673489 0.97
Malic Acid SCHEMBL14125844 0.97 SMN1; SMN2 (1.00) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL856 0.97
Malic Acid SCHEMBL28355917 0.97 SMN1; SMN2 (1.00) SMN1; SMN2SLC22A6TET2TET3TET1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3570977-B1 A PROCESS FOR PREPARING A MOLDING COMPRISING ZINC AND A TITANIUM-CONTAINING ZEOLITE BASF SE (DE) 2026-04-08 EP claimed
EP-4017462-B1 ORAL CARE COMPOSITIONS CONTAINING INULIN COLGATE PALMOLIVE CO (US) 2026-04-01 EP claimed
US-20250281374-A1 Dentifrice Compositions Comprising Tin Ions PROCTER & GAMBLE (US) 2025-09-11 US claimed
US-12350353-B2 Synthetic enamel and uses thereof TRUSTEES OF BOSTON UNIVERSITY (US) 2025-07-08 US claimed
US-12337047-B2 Dentifrice compositions comprising tin ions THE PROCTER & GAMBLE COMPANY (US) 2025-06-24 US claimed
US-12337046-B2 Oral care compositions comprising tin ions PROCTER & GAMBLE (US) 2025-06-24 US claimed
CN-119873821-A Rice hull sodium ion battery carbon negative electrode material and preparation method thereof 福建世记华钠新能源科技集团有限公司 2025-04-25 CN claimed
CN-119776007-A Cu-MTD etching solution composition for protecting oxide semiconductor 四川和晟达电子科技有限公司 2025-04-08 CN claimed
CN-119707558-A Mineral nutrition type rice seedling strengthening agent based on seedling raising matrix 中国水稻研究所 2025-03-28 CN claimed
CN-119461333-A Preparation method of multi-element doped asphalt-based hard carbon material for sodium ion battery cathode and battery 山东遥米新能源科技有限公司 2025-02-18 CN claimed
US-20040042978-A1 Method and composition for the treatment of epidermal irritations and infections MEININGER, LEIGH R., TRUSTEE IN BANKRUPTCY 2004-03-04 US claimed
US-20040033260-A1 Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc THE PROCTER & GAMBLE COMPANY (US) 2004-02-19 US claimed
CN-1311628-A Methods and compositions for treating skin allergies and infections WILLIAM J EMBRO (US) 2001-09-05 CN claimed
EP-1085804-A1 METHOD AND COMPOSITION FOR THE TREATMENT OF EPIDERMAL IRRITATIONS AND INFECTIONS Embro, William J. (US) 2001-03-28 EP claimed
WO-1999063816-A1 METHOD AND COMPOSITION FOR THE TREATMENT OF EPIDERMAL IRRITATIONS AND INFECTIONS EMBRO WILLIAM J (US) 1999-12-16 WO claimed
CN-1161776-A Green-plant treatment method capable of greatly prolonging period of inserting in bottle and storage period, and treatment liquid thereof ZHANG CHENGZHI (CN) 1997-10-15 CN claimed
CN-1144599-A Treatment method and liquid for withered green plant recovering its active state ZHANG CHENGZHI (CN) 1997-03-12 CN claimed
CN-1012682-B POLYVINYL CHLORIDE RESIN COMPOSITION FOR POWDER MOLDING SUMITOMO CHEMICAL CO (JP) 1991-05-29 CN claimed
US-4861816-A Polyvinyl chloride resin composition for powder molding SUMITOMO CHEMICAL COMPANY (JP) 1989-08-29 US claimed
CN-87105970-A The poly (vinyl chloride) resin composition that is used for powder molding 1988-08-10 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040033260-A1 Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc ZC3HAV1, ZC3HAV1L, SLC39A3 SMN1; SMN2 4357/4885SLC22A6 597/4885TET2 4243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.